Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study

References

• IDF Diabetes Atlas5th ed [homepage on the Internet]BrusselsInternational Diabetes Federation2011 [updated November 14, 2012; cited October 8, 2012]. Available from: http://www.idf.org/diabetesatlas/Accessed December 13, 2012
   Google Scholar
• Diabetes, fact sheet no 312 [webpage on the Internet]GenevaWorld Health Organization2012 [updated Sep 2012]. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/index.htmlAccessed December 13, 2012
   Google Scholar
• Centers for Disease Control and PreventionPrevalence and incidence1999 Diabetes Surveillance ReportAtlanta, GAUS Department of Health and Human Services, Centers for Disease Control and Prevention2004
   Google Scholar
• KanavosPvan den AardwegSSchurerWDiabetes Expenditure, Burden of Disease and Management in 5 EU CountriesLondonLSE Health, London School of Economics2012 Available from: http://www2.lse.ac.uk/LSEHealthAndSocialCare/research/LSEHealth/MTRG/LSEDiabetesReport26Jan2012.pdfAccessed December 20, 2012
   Google Scholar
• LeonardDTComparative effectiveness and real-world evidenceAm J Manag Care201016641041120560684
   PubMed Web of Science ®Google Scholar
• DreyerNASchneeweissSMcNeilBJGRACE InitiativeGRACE principles: recognizing high-quality observational studies of comparative effectivenessAm J Manag Care201016646747120560690
   PubMed Web of Science ®Google Scholar
• WareJHHamelMBPragmatic trials – guides to better patient care?N Engl J Med2011364181685168721542739
   PubMed Web of Science ®Google Scholar
• MannCJObservational research methods. Research design II: cohort, cross sectional, and case-control studiesEmerg Med J2003201546012533370
   PubMed Web of Science ®Google Scholar
• LigthelmRJBorziVGumprechtJKawamoriRWenyingYValensiPImportance of observational studies in clinical practiceClin Ther200729Spec12841292
   Web of Science ®Google Scholar
• BarnettAHBurgerJJohnsDTolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trialClin Ther200729112333234818158075
   PubMed Web of Science ®Google Scholar
• HeineRJVan GaalLFJohnsDExenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trialAnn Intern Med2005143855956916230722
   PubMed Web of Science ®Google Scholar
• NauckMADuranSKimDA comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority studyDiabetologia200750225926717160407
   PubMed Web of Science ®Google Scholar
• RayJABoyeKSYurginNExenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomesCurr Med Res Opin200723360962217355742
   PubMed Web of Science ®Google Scholar
• MittendorfTSmith-PalmerJTimlinLHappichMGoodallGEvaluation of exenatide vs insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German settingDiabetes Obes Metab200911111068107919732121
   PubMed Web of Science ®Google Scholar
• BrandleMErny-AlbrechtKMGoodallGSpinasGAStreitPValentineWJExenatide versus insulin glargine: a cost-effectiveness evaluation in patients with type 2 diabetes in SwitzerlandInt J Clin Pharmacol Ther200947850151519640359
   PubMed Web of Science ®Google Scholar
• GoodallGCostiMTimlinL[Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus]Endocrinol Nutr2011587331340 Spanish21719364
   PubMedGoogle Scholar
• MisurskiDLageMJFabunmiRBoyeKSA comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargineAppl Health Econ Health Policy20097424525419905038
   PubMedGoogle Scholar
• PawaskarMZagarASugiharaTShiLHealthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide bid or glargine: a retrospective database analysisJ Med Econ2011141162721158486
   PubMedGoogle Scholar
• BaserOWeiWBaserEXieLClinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide bidJ Med Econ201114667368021892858
   PubMedGoogle Scholar
• MatthaeiSReaneyMMathieuCPatients with type 2 diabetes initiating exenatide BID or insulin in clinical practice: CHOICE studyDiabetes Ther201231622714818
   PubMedGoogle Scholar
• MathieuCÖstensonCGMatthaeiSUsing exenatide twice daily or insulin in clinical practice: results from CHOICEDiabetes Therapy
   Web of Science ®Google Scholar
• ZinmanBSchmidtWEMosesALundNGoughSAchieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programmeDiabetes Obes Metab2012141778221883806
   PubMed Web of Science ®Google Scholar
• MalandaULWelschenLMRiphagenIIDekkerJMNijpelsGBotSDSelf-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin [review]Cochrane Database Syst Rev20121CD00506022258959
   PubMed Web of Science ®Google Scholar
• ClarCBarnardKCumminsERoylePWaughNAberdeen Health Technology Assessment GroupSelf-monitoring of blood glucose in type 2 diabetes: systematic reviewHealth Technol Assess201014121140
   Web of Science ®Google Scholar
• GaleEAPost-marketing studies of new insulins: sales or science?BMJ2012344e397422692652
   PubMed Web of Science ®Google Scholar
• YudkinJSPost-marketing observational trials and catastrophic health expenditureBMJ2012344e398722692653
   PubMed Web of Science ®Google Scholar
• ArodaVRHenryRRHanJEfficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic reviewClin Ther20123461247125822608780
   PubMed Web of Science ®Google Scholar